Monoclonal Antibody Approaches to Cancer Therapy

This article discusses the usage of Bevacizumab, monoclonal antibodies in cancer therapy and comparison from traditional approaches such as chemotherapy and radiotherapy. It covers the mechanism of action, benefits of existing therapeutic strategies used for cancer and varied disadvantages related to taking monoclonal antibodies.

Monoclonal antibody
approaches to cancer therapy

Introduction
Monoclonal antibodies are higher essential in triggering specific rise in individuals
immune system within body, which further develops response which has significant impact on
destroyed outer wall membrane in cancer cell. Monoclonal antibodies trigger immune system
responses immediately, which destroys outer wall of cancer cell, blocking cell growth effectively
for stopping spread of cancer. It further blocks connection between cancer cell and proteins, and
also primitively improvises body response to cancer. Bevacizumab is medication, used to treat
number in varied types of cancers within medical science and specific eye disease where it is
given by slow injection into veins. It is also used for colon cancer, within medical science.
Research will examine focus on usage of bevacizuma, monoclonal antibodies in cancer therapy
and comparison from traditional approaches such as chemotherapy and radiotherapy. Study will
discuss mechanism of action, benefits of existing therapeutic strategies used for cancer and
varied disadvantages related to taking monoclonal antibodies.
Use of Monoclonal antibody- Bevacizumab in cancer therapy
As per the views of Nasu and et.al, (2022), Bevacizuma is one of the most effective
monoclonal antibody used within treatment of cancer, which targets specific cancer cell protein
called vascular endothelial growth factor. It helps cancer to grow blood vessels, to stop growth of
cancer cells in body which is one of the most effective aspect found in antibodies. Research by
author explains that Bevacizuma is used to treat medical cancer of colon (large intestine), rectum
that has spread into body. It is used to treat lung cancer which spread into nearby tissues, that
cannot be removed by surgeries or therapies. It can be also analysed that Bevacixuma works
differently from traditional treatment chemotherapy, where it holds huge significance with
implementation of new technology.
The specific purpose of Bevacixuma is related to prevent growth of new blood vessels
within body, where this specifically includes normal vessels and blood vessels that fed tumours.
It has been approved for treatment of colorectal cancer, where it further has been approved for
treating lung cancer. Bevacixuma treats glioblastoma, which has been improved or has come
back after treatment with previous taken medications.. Combination with other chemotherapy

medications, enables to treat cervical cancer, that begins with opening of uterus. It is humanized
monoclonal antibody directed against circular vascular growth factor, where it has vitally
become first anti-angiogenic agent, which has been found to be approved by US drug
administration for treatment of cancer. Also, Monoclonal antibody has been found to be highly
crucial for improvising further extensive improvement in patient health condition in proper
timely format.
Comparison from traditional approaches such as chemotherapy and radiotherapy
As noted by Ambrosin. and et.al (2022), in comparison of Bevacixuma, with traditional
approaches such as chemotherapy and radiotherapy, there is effective new advanced treatment
with usage of new of technology. Chemotherapy leads to gum sores, gastrointestinal problems
and skin change in cancer patients. There is change in individual weight, physical symptoms
along with prolonged sickness and hair loss by taking chemotherapy. Research in recent study
has shed light on fact that Bevacixuma has very less side effects in comparison with traditional
chemotherapy treatments. This explains Bevacixuma us has been found to be effective, and also
further bringing timely improvement in cancer patients condition.
Also monoclonal antibody, blocks connection found within between cancer cell and
proteins structure that promote cell growth which is specific activity that is necessary for
survival. In comparison with traditional chemotherapy treatments for cancer, there is anaemia,
nausea and vomiting experienced by patients. Also there is appetite changes found along with
constipation, with chemotherapy treatment within patients conditions which lowers better long
term improvement in recovery. There are cognitive difficulties, hearing problems and increased
risk of blood clotting along with lung problems and reproductive changes. When compared with
usage of Bevacixuma, chemotherapy is highly long term duration treatment of cancer. It also
often leads to depressive mental conditions, where this hampers specific living conditions for
gaining medical recovery within long term recovery period.
As per the views of .Renpen and et.al, (2022), author critically argues Bevacizumab
prevent blood vessels from reaching tumour, where it starves the tumour for second line
treatment after first line treatment. The use of new advanced technology, within monoclonal
antibody approach to cancer therapy has numerous benefits for patients as compared with
chemotherapy traditional treatment. Bevacizumab, is widely effective for further improvised
treatments of cancer patient and also found to be improved on for timely healing.

Mechanism of action
As noted by Lu and et.al, (2022), Bevacizumab within specific mechanism of action acts
by selectively binding circulating VEGF, which also further inhibits binding to cell surface
receptors within body. It also leads to practical reduction within microvascular growth of tumour
blood vessels. It further leads to reduced blood supply to tumour tissues, injection products are
administered by doctors where this needs to be taken once every 2 or 3 week. Bevacizumab is
found to be bind to soluble VEGF, which further inhibits molecules to its receptors on surface of
endothelial cells. It is a non-specific VEGF, where the inhibitor is two binding to endothelial cell
receptors, in which reduction in activity inhibits angiogenesis, vascular permeability within
patient body. The antibody is typically given by transcojunctival intravitreal injections into
posterior segment, used in form of tropical drops. Bevacizumab is monoclonal anti-vascular
endothelial growth factor antibody , found to be crucial significant and used in combination with
agents for treatment of many types of cancer.
Author in recent findings within study has also critically shed light on fact that,
transcription of VEGF protein is induced by 'Hypoxia inducible factor'. The cancer cells promote
tumour angiogenesis by releasing VEGF, which results in creation of immature disorganized
vascular network. It can be further analysed that hypoxic micro-environment, promoted by
cancer cells favours survival of more aggressive tumour cells within body. This gives rise to
challenging environment for immune cells to respond, due to which Bevacizumab has become
one of the most effective drug within cancer treatment. It also prevents further formation of new
blood vessels, decreases tumour vasculature and reduces tumour blood supply among individuals
within body in cancer patients. Bevacizumab also known as Avastin is designed to block protein
called vascular endothelial growth factor of VEGF (Saravanakuma. and et.al, 2022). It prevents
growth of new blood vessels, including normal blood vessels within cancer patient body where it
has major role in controlling blood vessel formation. This modulates tumour induced
immunosuppression, where it has specific impact on body within cancer patient body. The
immunomodulatory properties further signifies that Bevacizumab needs to be given by further
taking care of patient medication situation and improving further diagnosis. Mechanism of action
in Bevacizumab, has bee found to be also effective for developed new treatments for cancer
patients within recent time period for extended new improvement as per medication.

However, as per the views of Vetre and et.al, 92022). Research on other hand has
contrasted views about Bevacizumab mechanism where it needs to be taken specifically by
doctor guidance and medical approval. The author specifies that Bevacizumab precautions
needs to be taken specific care for improving cancer patient critical condition. It can be also
analysed that further heading attention towards medical history, and dietary specific conditions
are integral for Bevacizumab usage in cancer treatment. It enables treatments within various
types of cancer, to be better improved and also further new advancement be given among further
medical aspects. Research within recent findings, have also analysed that varied significant
aspects correlated to larger improved treatment efficacy for cancer patient.
Evaluation of existing therapeutic strategies for cancer
As per the views of Yadav and et.al, (2022), Bevacizumab microbial, targets cancel cell
protein called vascular endothelial growth factor which significantly stop cancer to grow blood
vessels. This enables, maintenance of food and oxygen from blood, where blood supply is
hindered from growing among cancer patient. The antiangiogenic drug is used to treat certain,
specific type of brain tumour as well as cancers in kidney, colon along with rectum and lungs
within human. Avastin is usually also given as combination of cancer medicines, where this has
been also found to be one of the most effective monoclonal antibody used within treatment
within recent time. Recent working medical advancement has been also found to be specifically
effective, for strengthening treatment efficacy consistently within extended time period
parameters. The Bevacizumab is approved to treat metastatic, HER2- Negative breast cancer
among patients where it provides sufficient benefit In slowing disease progression for
outweighing significant risk analysis. Research in recent study by author, has analysed its timely
utilization effective for improving treatment condition for cancer patients.
However, there are some disadvantages of using prolonged Bevacizumab, on an
infrequent basis where this may cause blood clots to form and leads to serious medical
conditions leading to heart attack, stoke. This may need to be further needing immediate medical
attention if developed pain has been felt in pain, sudden vision changes and weaknesses. There is
also physiology change recognized among patient, who are under Bevacizumab, where they may
face confusion, less understanding capabilities and slurred speech on longer period parameters.
It can be analysed that by extending focus towards Bevacizumab, may cause infusion related
reactions within body which further extends to symptoms such as fever, dizziness or trouble

shaking. There is also light-headedness or fainting found in patient by receiving the
Bevacizumab, which may further hamper consciousness. It has been also found that by taking
up Bevacizumab, the treatments must be given by doctor under medical supervision and full
medical history analysis of patients for improvised recovery (Vetre and et.al, 2022).

REFRENCES
Books and Journals
Ambrosini, M. and et.al, 2022. Targeted protein degraders from an oncologist point of view: the
Holy Grail of cancer therapy?. Critical reviews in oncology/hematology, 169,
p.103532.
Lu, J., and et.al, 2022. Retrospective analysis of the preparation and application of
immunotherapy in cancer treatment. International Journal of Oncology, 60(2), pp.1-
23.
Nasu, H. and et.al, 2022. Platinum rechallenge treatment using gemcitabine plus carboplatin with
or without bevacizumab for platinum-resistant ovarian cancer. International Journal
of Clinical Oncology, pp.1-12.
Renpeng, Z. and et.al, 2022. A Randomized, Double-blind, Parallel-group Phase I Study
Comparing the Pharmacokinetics, Safety, and Immunogenicity of LY01008, a
Candidate Bevacizumab Biosimilar, with its Reference Product Avastin® in Healthy
Chinese Male Subjects. Expert Opinion on Biological Therapy, (just-accepted).
Saravanakumar, K. and et.al, 2022. A comprehensive review on immuno-nanomedicine for
breast cancer therapy: Technical challenges and troubleshooting
measures. International immunopharmacology, 103, p.108433.
Vetrei, C. and et.al, 2022. Novel Combinations of Human Immunomodulatory mAbs Lacking
Cardiotoxic Effects for Therapy of TNBC. Cancers, 14(1), p.121.
Yadav, A. and et.al, 2022. Advances in Delivery of Chemotherapeutic Agents for Cancer
Treatment. AAPS PharmSciTech, 23(1), pp.1-14.